Extended-release Onapristone
20P.829
Phase 2 small_molecule active
Quick answer
Extended-release Onapristone for Refractory Endometrial Adenocarcinoma is a Phase 2 program (small_molecule) at Context Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Context Therapeutics
- Indication
- Refractory Endometrial Adenocarcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active